Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck won approval from the U.S. Food and Drug Administration for a shot that protects against RSV, the most common cause of hospitalization among infants, STAT notes.

Merck’s RSV drug approval and a drug manufacturer winds down Mel Evans/AP By Elaine Chen June 10, 2025 National Biotech Reporter ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...